Form 4: TriSalus Life Sciences Director Acquires Shares and Options
SEC Form 4
Sean Murphy, a director and officer of TriSalus Life Sciences, reports acquiring shares and options in the company through recent transactions.
Summary
- On January 27, 2025, Sean Murphy, a director and officer at TriSalus Life Sciences, acquired 12,500 shares of common stock as a restricted stock unit (RSU) award.
- These shares vest in four equal annual installments starting January 1, 2025, contingent upon continued service with the Issuer.
- On the same day, Murphy also purchased 15,000 shares at a weighted average price of $5.31, with individual transactions ranging from $5.09 to $5.55.
- On January 28, 2025, he purchased another 15,000 shares at a weighted average price of $5.17, with prices ranging from $4.94 to $5.35.
- Murphy also acquired an option to purchase 75,000 shares of common stock at an exercise price of $5.3, vesting in installments starting January 1, 2025, and expiring on January 26, 2035.
- Following these transactions, Murphy directly owns 63,288 shares and indirectly owns 197,732 shares through a trust and 357,535 shares through the Murphy Family Trust 2012.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. Insider buying can be a positive signal, but it's also part of standard compensation practices. The vesting schedule suggests a long-term commitment.
Positives
- The acquisition of shares and options by a director and officer could be seen as a positive signal, indicating confidence in the company's future prospects.
Future Outlook
The RSU Award and stock options vest over time, contingent on the Reporting Person's continued service with the Issuer.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC when company insiders, like directors and officers, trade in their company's stock. It provides transparency to the market about the transactions of those with privileged information.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their insiders.
- The vesting schedules and exercise prices of the stock options are typical for employee compensation packages in the biotech industry.
- Similar filings can be observed for executives at comparable companies like Exact Sciences (EXAS) or Guardant Health (GH).
Stakeholder Impact
- Shareholders may view the insider buying as a positive sign of confidence in the company's future.
- Employees may be motivated by the fact that a director and officer is increasing their stake in the company.
Key Dates
| Date | Description |
|---|---|
| 02/04/2004 | Date of Sean E Murphy TTEE U/A |
| 01/01/2025 | Vesting commencement date for RSU Award and stock options |
| 01/26/2035 | Expiration date for stock options |
| 01/27/2025 | Date of RSU Award grant and purchase of common stock |
| 01/28/2025 | Date of purchase of common stock |
| 01/29/2025 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.